Experts discuss the variability of non-muscle invasive bladder cancer (NMIBC) in terms of staging and risk stratification and how they navigate these diagnoses with their patients.

Experts discuss the variability of non-muscle invasive bladder cancer (NMIBC) in terms of staging and risk stratification and how they navigate these diagnoses with their patients.

Experts provide an overview of non-muscle invasive bladder cancer (NMIBC) and common procedures for diagnosis. Now Viewing EP: 1. A Comprehensive Overview of NMIBC ...

How does the ability to administer treatments less frequently, once every 3 months, reduce the resource expenditure in your clinic (eg, staff time and equipment use, allocating more time to patients ...

"I use a multi-pronged approach. I focus on behavior modification, nutrition, hydration, and exercise," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, gives an overview of her clinic ...

"There are some very strict IC diets that have been published, and I've had a handful of patients who have really found them helpful," says J. Quentin Clemens, MD, MSCI. In this video, J. Quentin ...

From an operational standpoint, how important is it that these treatments can be administered by urologists locally, without the need to refer patients to oncology centers? Please discuss overall ...

TLX007-CDx, a PSMA-PET imaging agent for prostate cancer, may offer an extended distribution profile compared to current agents, with an FDA decision expected by March 24, 2025. Gepotidacin, a ...

The CaRe PC trial evaluates INKmune therapy in mCRPC, focusing on safety and anti-tumor activity across three dose levels. The trial has expanded to include veterans, with the first patient dosed at ...

Urology Coding Q&A: Can G2211 be reported regardless of payer?

EMA's acceptance of Anktiva's application marks a significant step for NMIBC treatment in Europe, following FDA approval in the US. The QUILT 3.032 trial showed a 71% complete response rate for ...

"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along ...